Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 5/20 | 0.42 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.38 |
| ▸ | LRRK2 | Q5S007 | 3/20 | 0.37 |
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.35 |
| ▸ | RAF1 | P04049 | 2/20 | 0.35 |
| ▸ | BRAF | P15056 | 2/20 | 0.35 |
| ▸ | ITGB2 | P05107 | 2/20 | 0.35 |
| ▸ | ICAM1 | P05362 | 2/20 | 0.35 |
| ▸ | ITGAL | P20701 | 2/20 | 0.35 |
| ▸ | TYK2 | P29597 | 1/20 | 0.34 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.33 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.33 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.33 |
| ▸ | PROKR1 | Q8TCW9 | 1/20 | 0.33 |
| ▸ | ACACB | O00763 | 3/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14868421 | 0.88 | ITGB2 (0.45) | HRH3LRRK2HRH4ITGB2ICAM1 | |
| SCHEMBL14868472 | 0.88 | ITGB2 (0.45) | HRH3LRRK2HRH4ITGB2ICAM1 | |
| SCHEMBL14868458 | 0.88 | ITGB2 (0.45) | HRH3LRRK2HRH4ITGB2ICAM1 | |
| SCHEMBL11960320 | 0.84 | LRRK2 (0.45) | HRH3LRRK2HRH4ITGB2ICAM1 | |
| SCHEMBL15274620 | 0.83 | HRH3 (0.42) | HRH3LRRK2HRH4ITGB2ICAM1 | |
| SCHEMBL25653339 | 0.81 | LRRK2 (0.45) | HRH3LRRK2ITGB2ICAM1ITGAL | |
| SCHEMBL11960323 | 0.77 | SMN1; SMN2 (0.46) | HRH3LRRK2HRH4 | |
| SCHEMBL11981511 | 0.77 | EGLN2 (0.40) | HRH3EGLN2LRRK2HRH4TYK2 | |
| SCHEMBL13034784 | 0.76 | SMN1; SMN2 (0.49) | HRH3LRRK2HRH4 | |
| SCHEMBL12296243 | 0.75 | HRH3 (0.51) | HRH3LRRK2HRH4RAF1BRAF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9309240-B2 | Pyrazolopyridine compounds, compositions and methods of use | GENENTECH, INC. (US) | 2016-04-12 | — | — | US | disclosed |
| US-20140171408-A1 | AZABENZOTHIAZOLE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | GENENTECH, INC. (US) | 2014-06-19 | — | — | US | disclosed |
| US-20130252941-A1 | PYRAZOLOPYRIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | F. HOFFMANN-LA ROCHE AG (CH) | 2013-09-26 | — | — | US | disclosed |
| US-20130096104-A1 | IMIDAZOPYRIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | GENENTECH, INC. (US) | 2013-04-18 | — | — | US | disclosed |
| US-20120202788-A1 | AZABENZOTHIAZOLE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | F. HOFFMANN-LA ROCHE AG (CH) | 2012-08-09 | — | — | US | disclosed |
| US-20120202788-A1 | AZABENZOTHIAZOLE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | F. HOFFMANN-LA ROCHE AG (CH) | 2012-08-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130096104-A1 | IMIDAZOPYRIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | TYK2, IRAK1, IRAK4 | HRH3 307/4885EGLN2 3527/4885LRRK2 1710/4885 |
| US-20130252941-A1 | PYRAZOLOPYRIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | P2RX5, P2RX4, P2RY1 | HRH3 171/4885EGLN2 2911/4885LRRK2 3622/4885 |
| US-20140171408-A1 | AZABENZOTHIAZOLE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | F12, CHRM1, NPY1R | HRH3 605/4885EGLN2 4552/4885LRRK2 4285/4885 |
| US-20120202788-A1 | AZABENZOTHIAZOLE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | F12, CHRM1, NPY1R | HRH3 605/4885EGLN2 4552/4885LRRK2 4285/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.